Mankind Pharma, India’s fourth-largest pharmaceutical company, has completed a sweeping, multi-year transformation of its global supply chain and strategic procurement function, aiming to improve access to medicines, enhance supply reliability, and drive scalable growth. 

 

The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks.

 

“This transformation goes beyond efficiency, delivering sharper visibility, stronger control, and quality and compliance by design,” said Arjun Juneja, Chief Operating Officer, Mankind Pharma. 

 

“By integrating demand, procurement, manufacturing, inventory management, and execution through advanced analytics and AI-augmented insights, we have strengthened our ability to anticipate demand, manage volatility, and respond with speed and precision across markets. It enables us to scale responsibly and sustainably, reinforcing our commitment to Availability, Quality, and Affordability, while building long-term resilience into our operations.”

 

The overhaul merges two critical operating pillars into a unified, end-to-end backbone linking planning intelligence with execution performance. Mankind Pharma has deployed an integrated planning platform connecting demand forecasting, manufacturing, inventory, and distribution across more than 25 international markets. Powered by AI-driven insights, the platform has boosted forecast accuracy, improved cross-functional alignment, and enabled faster, more responsive planning.

 

In parallel, the company completed an 18-month revamp of its strategic sourcing and procurement function, standardizing processes, introducing digital automation, and applying analytics-led decision-making to improve cost discipline, governance, and supplier collaboration.

 

The results are striking. Across 30 manufacturing facilities and more than 50 distribution centers, the platform has cut drug stock-outs by 75% and optimized inventory by up to 20%. The procurement transformation has clarified sourcing ownership, automated routine activities, and given leadership sharper visibility into spending, supplier performance, and supply chain risks—all while safeguarding quality, compliance, and supply continuity.

 

“Working closely with Mankind Pharma, Accenture helped reimagine and strengthen the company's operating model for the long term,” said Jignesh Vora, managing director and lead - Life Sciences, Accenture in India. 

 

“By combining AI-led, data-driven capabilities with deep life sciences and supply chain expertise, we enabled a more predictive and resilient supply chain and procurement ecosystem—driving better decision-making at scale, improving access to medicines, and supporting sustainable growth in a volatile and regulated environment.”

 

This transformation reinforces Mankind Pharma’s commitment to operational excellence, disciplined execution, and long-term resilience, while keeping its focus on delivering quality and affordable medicines. With healthcare systems evolving globally, the company is now positioned to respond with agility, consistency, and scale—strengthening trust among patients, partners, and stakeholders in India and abroad.